Inclusion Criteria:  • Age range between 25 and 40 years  Patients with severe chronic periodontitis having probing depth (PD) ≥6 mm and clinical attachment loss (CAL) ≥5 mm , or Stage III periodontitis Patient having vertical bone loss ≥3 mm (distance between alveolar crest and base of the defect as confirmed by preoperative intraoral periapical radiographs using standardized parallel technique.) Good compliance with the plaque control instructions following initial therapy Availability for follow up and maintenance program.  Exclusion Criteria:  • Patient with any systemic disease or conditions  Patient using antibiotic, anti-inflammatory, and immunosuppressive therapy during the preceding 3 months before the start of trial and during the study. Patients who have undergone any periodontal treatment in the last 6 months Pregnant and Lactating. Reported allergy to any type of statins Subjects who were tobacco or alcohol users Vulnerable group of patients (e.g.: prisoners , handicapped , or decisionally impaired individuals )